

Human Recombinant Prostanoid Receptor DP2 Stable Cell Line Cat. No. M00436 Version 07302020

I.	Introduction
II.	Background1
III.	Representative Data
IV.	Thawing and Subculturing
٧.	References
VI.	Limited Use License Agreement

I. INTRODUCTION

Catalog Number: M00436

Cell Line Name: CHO-K1/DP2/Gα15 Gene Synonyms: GPR44, CRTH2

Expressed Gene: Genbank Accession Number NM_004778; no expressed tags

Host Cell: CHO-K1/Gα15 Culture Properties: Adherent

Quantity: Two vials of frozen cells (>1×10⁶ per vial)

Stability: More than 16 passages

Application: Functional assay for DP2 receptor

Freeze Medium: 45% culture medium, 45% FBS (Cat. #10099-141, Gibco), 10% DMSO (Cat.

#D2650, Sigma)

Complete Growth Medium: Ham's F12 (Cat. #11765, Life Technologies), 10% FBS

Culture Medium: Ham's F12, 10% FBS, 100 µg/ml Hygromycin B (Cat. #10687010, Invitrogen),

3 µg/ml puromycin (Cat. #A11138-03, Gibco)

Mycoplasma Status: Negative*

Storage: Liquid nitrogen immediately upon receipt

II. BACKGROUND

Prostaglandin D (2) (PGD(2)) is derived from arachidonic acid and binds with high affinity to the G-protein coupled receptors prostanoid DP(1) and DP(2). Interaction with DP(2) results in cell chemotaxis, eosinophil degranulation, eosinophil shape change, adhesion molecule upregulation and Th2 cytokine production. In allergic rhinitis and allergic asthma PGD(2) is released from mast cells in response to allergen challenge and may trigger symptoms such as sneezing, rhinorrhea, pruritus, mucus hypersecretion and pulmonary inflammation. GenScript's cloned human DP2-expressing cell line co-expressing $G\alpha15$ is made in the CHO-K1 host.

^{*} The mycoplasma test was performed with MycoAlert™ PLUS Mycoplasma Detection Kit of Lonza.



III. REPRESENTATIVE DATA

Concentration-dependent stimulation of intracellular calcium mobilization by PGD2 in CHO-K1/DP2/Gα15 cells




Figure 1. PGD2-induced concentration-dependent stimulation of intracellular calcium mobilization in CHO-K1/DP2/G α 15 cells. The cells were loaded with Calcium-4 prior to being stimulated with agonist, PGD2. The intracellular calcium change was measured by FLIPR. The relative fluorescent units (RFU) were plotted against the log of the cumulative doses (5-fold dilution) of PGD2 (Mean \pm SD, n = 2). The EC₅₀ of PGD2 on this cell was 15 nM.

Notes:

- 1. EC₅₀ value is calculated with four parameter logistic equation:
 - Y=Bottom + (Top-Bottom)/ (1+10^((LogEC₅₀-X)*HillSlope))
 - X is the logarithm of concentration. Y is the response
 - Y is RFU and starts at Bottom and goes to Top with a sigmoid shape.
- 2. Signal to background Ratio (S/B) = Top/Bottom

IV. THAWING AND SUBCULTURING

Thawing Protocol

- 1. Remove the vial from liquid nitrogen tank and thaw cells quickly in a 37°C water-bath.
- Just before the cells are completely thawed, decontaminate the outside of the vial with 70% ethanol and transfer the cells to a 15 ml centrifuge tube containing 9 ml of complete growth medium.
- 3. Pellet cells by centrifugation at 200 x g force for 5 min, and remove the medium.
- 4. Resuspend the cells in complete growth medium.
- 5. Transfer the cell suspension to a 10 cm dish with 10 ml of complete growth medium.
- 6. Grow the cells in incubator with 37°C, 5 %CO₂.
- 7. In the following day, replace the cells with fresh medium contains antibiotic.

Sub-culturing Protocol

Remove the culture medium from cells.



- 2. Wash cells with PBS (pH=7.4) to remove all traces of serum that contains trypsin inhibitor.
- 3. Add 2.0 ml of 0.05% (w/v) Trypsin- EDTA (GIBCO, Cat No. 25300) solution into 10 cm dish and observe the cells under an inverted microscope until cell layer is dispersed (usually within 3 to 5 minutes).

Note: To avoid cells clumping, do not agitate the cells by hitting or shaking the dish while waiting for the cells detach. If cells are difficult to detach, please place the dish in 37°C incubator for ~2 min.

- 4. Add 6.0 to 8.0 ml of complete growth medium into dish and aspirate cells by gently pipetting.
- 5. Centrifuge the cells at 200 x g force for 5min, and remove the medium.
- 6. Resuspend the cells in culture medium and add the cells suspension to new culture dish.
- 7. Grow the cells in incubator with 37°C, 5 %CO₂.

Subcultivation Ratio: 1:3 to 1:8

Medium Renewal: Every 2 to 3 days

V. REFERENCES

- Stebbins KJ et al. (2010) Therapeutic efficacy of AM156, a novel prostanoid DP2 receptor antagonist, in murine models of allergic rhinitis and house dust mite-induced pulmonary inflammation. Eur J Pharmacol. 638(1-3):142-9
- Mathiesen JM et al. (2006) On the mechanism of interaction of potent surmountable and insurmountable antagonists with the prostaglandin D2 receptor CRTH2. Mol Pharmacol. 69:1441–1453

GenScript USA Inc,

860 Centennial Ave. Piscataway, NJ 08854 Toll-Free: 1-877-436-7274

Tel: 1-732-885-9188, Fax: 1-732-210-0262

Email: product@genscript.com
Web: http://www.genscript.com

For Research Use Only.



Limited Use License Agreement

This is a legal agreement between you (Licensee) and GenScript USA Inc. governing use of GenScript's stable cell line products and protocols provided to licensee. By purchasing and using the stable cell line, the buyer agrees to comply with the following terms and conditions of this label license and recognizes and agrees to such restrictions:

- The products are not transferable and will be used at the site where they were purchased.
 Transfer to another site owned by buyer will be permitted only upon written request by buyer followed by subsequent written approval by GenScript.
- 2) The purchaser cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party.
- 3) The products sold by GenScript are for laboratory and animal research purposes only. The products are not to be used on humans, for consumption, or for any unlawful uses.

GenScript USA Inc. will not assert against the buyer a claim of infringement of patents owned or controlled by GenScript USA Inc. and claiming this product based upon the manufacture, use or sale of a clinical diagnostic, therapeutic and vaccine, or prophylactic product developed in research by the buyer in which this product or its components has been employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on the use of this product for other purposes, contact Marketing Department, GenScript USA Inc., 860 Centennial Ave. Piscataway, NJ 08854, U.S.A. Phone: 1-732-885-9188. Fax: 1-732-210-0262. Email: marketing@genscript.com.